ACTIVE

Exo-Harvest

Export PDF
Financial year 2025 · closed on 31/12/2025
Net result
-191 k €
-13.8% YoY
Gross margin
-2,1 k €
+94.6% YoY
Equity
151,8 k €
-55.7% YoY

What does Exo-Harvest do?

Exo-Harvest is a Private limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi.

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0803.425.264
Incorporation
30/06/2023
Legal form
Private limited company
Registered office
Rue Clément Ader 10
6041 Charleroi · WallonieSee on map
Contributed capital
553 142,00 €
Latest accounts
31/12/2025
Activities (NACE)
72101Research and experimental development on natural sciences and engineering· main72110Research and experimental development on biotechnology
Contacts
2 public details availableLog in to view
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 3 financial years

202520242023
Income statement
Gross margin-2,1 k €-39,3 k €-6,4 k €
EBITDA-6,6 k €-41 k €-6,4 k €
Operating result-177,9 k €-159 k €-42,5 k €
Net result-191 k €-167,8 k €-42,5 k €
Balance sheet
Equity151,8 k €342,8 k €163 k €
Total assets764,1 k €471,8 k €226 k €
Cash1,4 k €2,6 k €65,2 k €
Debts612,3 k €129,1 k €60,5 k €
Estimate

Indicative valuation

As an indication, this company is worth

between 100 k€ and 250 k€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2025 · 3 active · 3 ended

Active mandates

JSMAL BioTech Consulting

Director · since 29 août 2024 · 0641.867.905

Represented by Jean Smal

Active
TONGLET CONSULT

Managing director · since 29 août 2024 · 0653.978.750

Represented by Frédéric Tonglet

Active
JPP CONSULTING

Director · since 30 juin 2023 · 0829.890.923

Represented by Jean Paul Prieels

Active

Ended mandates

JSMAL BioTech Consulting

Director · since 27 août 2024 · 0641.867.905

Represented by Jean Smal

Ended
TONGLET CONSULT

Managing director · since 27 août 2024 · 0653.978.750

Represented by Frédéric Tonglet

Ended
JPP CONSULTING

Director · since 30 juin 2023 · until 27 août 2024 · 0829.890.923

Represented by Jean Paul Prieels

Ended
At this address

Other companies at this address

CompanyCBE no.
2 Bridge WL● Active
1003.906.745
3D Fibroscreen● Active
1022.772.354
AdipoPharma Belgique● Active
1008.146.338
ATRYON BELGIUM● Active
0751.698.530
Brussels South Charleroi BioPark Dev● Active
0479.250.670
ConvEyXo● Active
0725.874.259
CONVEYXO GROUP● Active
1016.957.797
ELKEDONIA BELGIUM● Active
1021.635.177
ENDO TOOLS THERAPEUTICS● Active
0807.570.233
Enodia Therapeutics Belgium● Active
1039.324.811
EU BIOTECH CAMPUS● Active
0776.668.706
Hemastatx● Active
1019.406.058
Immunofusion● Active
0804.563.629
ImmunXperts● Active
0552.755.587
INCHINN THERAPEUTICS● Active
0799.914.755
INSTAR BELGIQUE● Active
1039.395.085
KOKUMA● Active
0799.078.377
LYS MEDICAL● Active
0688.626.061
MILEUTIS● Active
1011.400.984
Nexelis Europe● Active
0744.498.061
Annual accounts

Full financial information

202520242023
Type of accountAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202430/06/2023
Closing of the financial year31/12/202531/12/202431/12/2023
Length of the financial year12 months12 months7 months
Filing date15/07/202624/07/202530/08/2024
General meeting01/07/202630/06/202527/08/2024
Currency of the financial yearEUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

3 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202501/07/202615/07/2026FrenchPDF
Abridged model31/12/202430/06/202524/07/2025FrenchPDF
Abridged model31/12/202327/08/202430/08/2024FrenchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 k€ and 250 k€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 3 active · 3 ended

Active mandates

JSMAL BioTech Consulting

Director · since 29 août 2024 · 0641.867.905

Represented by Jean Smal

Active
TONGLET CONSULT

Managing director · since 29 août 2024 · 0653.978.750

Represented by Frédéric Tonglet

Active
JPP CONSULTING

Director · since 30 juin 2023 · 0829.890.923

Represented by Jean Paul Prieels

Active

Ended mandates

JSMAL BioTech Consulting

Director · since 27 août 2024 · 0641.867.905

Represented by Jean Smal

Ended
TONGLET CONSULT

Managing director · since 27 août 2024 · 0653.978.750

Represented by Frédéric Tonglet

Ended
JPP CONSULTING

Director · since 30 juin 2023 · until 27 août 2024 · 0829.890.923

Represented by Jean Paul Prieels

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Registered office18/11/2025
    SIEGE SOCIAL
    PDF
  • Capital / shares08/01/2025
    CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION,
    PDF
  • Mandates22/10/2024
    DEMISSION ET NOMINATION D'UN ADMINISTRATEUR DELEGUE A LA
    PDF
  • Registered office16/04/2024
    SIEGE SOCIAL
    PDF
  • Other26/01/2024
    DIVERS
    PDF
  • Other04/07/2023
    RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-191 k €↓
  2. 2024
    Annual accounts 2024-167,8 k €↓
  3. 2023
    Annual accounts 2023-42,5 k €
  4. 30/06/2023
    IncorporationPrivate limited company